During the last 10 to 15 years, the progressive introduction of noninvasive tests (NITs) for the
diagnosis and management of chronic liver diseases (CLDs) has had a major impact in …

Direct-acting antivirals (DAAs) have dramatically improved the management of chronic
hepatitis C (CHC). In this study, we investigated the effects of hepatitis C virus clearance on …

Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can
be cured in almost all infected patients. This has led to a number of clinical questions …

BACKGROUND Liver fibrosis is a common pathway of liver injury and is a feature of most
chronic liver diseases. Fibrosis progression varies markedly in patients with hepatitis C virus …

Background One of the most important questions is what happens with liver fibrosis
following a sustained virological response (SVR), although the current anti-HCV therapies …

Fibrosis, a common pathogenic pathway of chronic liver disease (CLD), has long been
indicated to be significantly and most importantly associated with severe prognosis …

The severity of liver fibrosis can be noninvasively evaluated by measuring liver stiffness (LS)
using transient elastography. This study aimed to evaluate the prognostic value of achieving …

Introduction With availability of direct‐acting antivirals (DAA), most persons with inherited
bleeding disorders are currently cured of hepatitis C virus (HCV) infection. The risk of liver …

Background Direct-acting antivirals (DAAs) lead to a high rate of sustained virologic
response (SVR) in chronic hepatitis C infection. The aim was to evaluate liver stiffness …

The risk of hepatocellular carcinoma (HCC) diminishes in patients with hepatitis C virus
(HCV)-related advanced chronic liver disease after virological cure. However, despite viral …